Novartis Pharma GmbH, in an information letter issued by the BfArM on February 2, 2026, has announced changes to the storage conditions and shelf life for Kisqali 200 mg film-coated tablets (active substance: ribociclib). The key changes include the removal of the requirement for refrigerated storage and an extension of the authorized shelf life to 2 years. The medicine should continue to be stored in its original packaging to protect it from moisture.

Healthcare providers and pharmaceutical distributors should update their inventory management and dispensing protocols to reflect these new storage requirements and the extended shelf life. While no specific compliance deadline is mentioned, it is advisable to implement these changes promptly to ensure proper product handling and patient safety. This update primarily affects the handling and storage practices for the specified medication.